Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Actos
Actos 15 mg tablets Actos 30 mg tablets Actos 45 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-091030 · Präparat HOS-084177
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In
vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel
blockers, and HMGCoA reductase inhibitors are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) phenprocoumon (HOS-091031) calcium (HOS-085615) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-08-28T15:56:00Z · SHA-256 9db485a8edb528eab1b3fb65eee070f4e61e0143333341420cf15c5240029983 · Passage 80c19268544672e4f2d2f5633ee370e99e19e7db77a19d2f3a9fbcadbbdc6f43 · Zeichen 0–647 im Abschnitt
Wechselwirkungen · Xeloda
Xeloda 150 mg film-coated tablets. Xeloda 500 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 10
HOS-091421 · Präparat HOS-084311
Coumarin-derivative anticoagulants: altered coagulation parameters and/or bleeding have been
reported in patients taking capecitabine concomitantly with coumarin-derivative anticoagulants such
as warfarin and phenprocoumon. These reactions occurred within several days and up to several
months after initiating capecitabine therapy and, in a few cases, within one month after stopping
capecitabine. In a clinical pharmacokinetic interaction study, after a single 20 mg dose of warfarin,
capecitabine treatment increased the AUC of S-warfarin by 57% with a 91% increase in INR value.
Since metabolism of R-warfarin was not affected, these results indicate that capecitabine down-
regulates isozyme 2C9, but has no effect on isozymes 1A2 and 3A4. Patients taking coumarin-
derivative anticoagulants concomitantly with capecitabine should be monitored regularly for
alterations in their coagulation parameters (PT or INR) and the anticoagulant dose adjusted
accordingly.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenprocoumon (HOS-091031) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-02T14:45:00Z · SHA-256 632b962270222a1b1c9626101f7ef2fdc0c5500039de7f68bd6fd6e7e22b7b52 · Passage f7452e2b078b6ee5dc45ef4e375246458e3f25c847078c541bd34cf7c6b48abd · Zeichen 1080–2047 im Abschnitt
Wechselwirkungen · Vfend
VFEND 50 mg film-coated tablets VFEND 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-109445 · Präparat HOS-093201
Erythromycin (1 g BID) Voriconazole Cmax and AUC ↔
[CYP3A4 inhibitor]
The effect of voriconazole on
either erythromycin or
azithromycin is unknown.
Rifabutin Concomitant use of voriconazole
[potent CYP450 inducer] and rifabutin should be avoided
Voriconazole Cmax 69% unless the benefit outweighs the
300 mg QD Voriconazole AUC 78% risk.
The maintenance dose of
Compared to voriconazole 200 mg voriconazole may be increased to
300 mg QD (coadministered BID, 5 mg/kg intravenously BID or
with voriconazole 350 mg Voriconazole Cmax 4% from 200 mg to 350 mg orally
BID)* Voriconazole AUC 32% BID (100 mg to 200 mg orally
BID in patients less than 40 kg)
(see section 4.2).
Careful monitoring of full blood
Rifabutin Cmax 195% counts and adverse reactions to
300 mg QD (coadministered Rifabutin AUC 331% rifabutin (e.g., uveitis) is
with voriconazole 400 mg Compared to voriconazole 200 mg recommended when rifabutin is
BID)* BID, coadministered with
voriconazole.
Voriconazole Cmax 104%
Voriconazole AUC 87%
Rifampicin (600 mg QD) Voriconazole Cmax 93% Contraindicated (see section
[potent CYP450 inducer] Voriconazole AUC 96% 4.3)
Anti-cancer agents
Glasdegib Although not studied, voriconazole If concomitant use cannot be
[CYP3A4 substrate] is likely to increase the plasma avoided, frequent ECG
concentrations of glasdegib and monitoring is recommended (see
increase risk of QTc prolongation. section 4.4).
Tretinoin Although not studied, voriconazole Dose adjustment of tretinoin is
[CYP3A4 substrate] may increase tretinoin recommended during treatment
concentrations and increase risk of with voriconazole and after its
adverse reactions (pseudotumor discontinuation.
cerebri, hypercalcaemia).
11
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) rifabutin (HOS-086262) vinblastine (HOS-086220) glasdegib (HOS-109446) vincristine (HOS-086219) azithromycin (HOS-088112) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) tretinoin (HOS-109447) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) erythromycin (HOS-084514) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 92969ff5c9d1e7ffb4a2f7eaf265abd9d2899e7061ac52ea8adefc4d660b4316 · Zeichen 4932–11582 im Abschnitt
Wechselwirkungen · Vfend
VFEND 200 mg powder for solution for infusion · Abschnitt 4.5 · PDF-Seite 43–44
HOS-109538 · Präparat HOS-093201
43
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) phenprocoumon (HOS-091031) prothrombin (HOS-085093) acenocoumarol (HOS-109456) phenytoin (HOS-084531) warfarin (HOS-085950) mephobarbital (HOS-109457)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage 5ae9bbe0daf742daaf2a160c7d91f0c8d54a2ad8a7e98684c6f63198d04c2a65 · Zeichen 10221–11996 im Abschnitt
Wechselwirkungen · Vfend
VFEND 40 mg/ml powder for oral suspension · Abschnitt 4.5 · PDF-Seite 75–76
HOS-109603 · Präparat HOS-093201
75
Tyrosine kinase inhibitors Although not studied, voriconazole If concomitant use cannot be
(including but not limited to: may increase plasma avoided, dose reduction of the
axitinib, bosutinib, concentrations of tyrosine kinase tyrosine kinase inhibitor and
cabozantinib, ceritinib, inhibitors metabolised by CYP3A4. close clinical monitoring is
cobimetinib, dabrafenib, recommended (see section 4.4).
dasatinib, nilotinib, sunitinib,
ibrutinib, ribociclib)
[CYP3A4 substrates]
Venetoclax Although not studied, voriconazole
Concomitant administration of
[CYP3A substrate] is likely to significantly increase
voriconazole is contraindicated
the plasma concentrations of at initiation and during
venetoclax. venetoclax dose titration phase
(see section 4.3). Dose reduction
of venetoclax is required as
instructed in venetoclax
prescribing information during
steady daily dosing; close
monitoring for signs of toxicity is
recommended.
Vinca Alkaloids (including but Although not studied, voriconazole Dose reduction of vinca alkaloids
not limited to: vincristine and is likely to increase the plasma should be considered.
vinblastine) concentrations of vinca alkaloids
[CYP3A4 substrates] and lead to neurotoxicity.
Anticoagulants
Warfarin (30 mg single dose, Maximum increase in prothrombin Close monitoring of prothrombin
coadministered with 300 mg time was approximately 2-fold. time or other suitable
BID voriconazole) anticoagulation tests is
[CYP2C9 substrate] recommended, and the dose of
anticoagulants should be adjusted
Other oral coumarins Although not studied, voriconazole accordingly.
(including but not limited to: may increase the plasma
phenprocoumon, concentrations of coumarins that
acenocoumarol) may cause an increase in
[CYP2C9 and CYP3A4 prothrombin time.
substrates]
Anticonvulsants
Carbamazepine and Although not studied, Contraindicated (see section
long-acting barbiturates carbamazepine and long-acting 4.3)
(including but not limited to: barbiturates are likely to
phenobarbital, mephobarbital) significantly decrease plasma
[potent CYP450 inducers] voriconazole concentrations.
Phenytoin Concomitant use of voriconazole
[CYP2C9 substrate and potent and phenytoin should be avoided
CYP450 inducer] unless the benefit outweighs the
risk. Careful monitoring of
300 mg QD Voriconazole Cmax 49% phenytoin plasma levels is
Voriconazole AUC 69% recommended.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): axitinib (HOS-109448) ceritinib (HOS-086215) dasatinib (HOS-086217) cobimetinib (HOS-109451) phenobarbital (HOS-085617) carbamazepine (HOS-085618) vinblastine (HOS-086220) vincristine (HOS-086219) phenprocoumon (HOS-091031) dabrafenib (HOS-109452) venetoclax (HOS-086143) lead (HOS-085592) prothrombin (HOS-085093) sunitinib (HOS-109453) ribociclib (HOS-109454) tyrosine (HOS-108875) acenocoumarol (HOS-109456) cabozantinib (HOS-109450) phenytoin (HOS-084531) warfarin (HOS-085950) bosutinib (HOS-109449) mephobarbital (HOS-109457) nilotinib (HOS-086218) ibrutinib (HOS-086226)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-21T15:15:00Z · SHA-256 e91b23f050e51d641bef6be84ca7a49bb0e71d249b5c23f29243dda478d37eaf · Passage f6b81055f3c718e14857cfd38d70a912e61bf8acd5f789552e442ecbfbe65b67 · Zeichen 7792–11614 im Abschnitt
Wechselwirkungen · Competact
Competact 15 mg/850 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-115219 · Präparat HOS-094245
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Studies in man suggest
no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In vitro studies have shown
no inhibition of any subtype of cytochrome P450. Interactions with substances metabolised by these
enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase
inhibitors are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) phenprocoumon (HOS-091031) calcium (HOS-085615) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-09T10:33:00Z · SHA-256 3615be1e7bbb8cfa815bb6a83c363e1a5d1ff5a97c3b12dfeb5eb3ed217ec618 · Passage af1a36ebd8e6d382b4c2625c2ba29f36d166e1b4fdb08dd1f0796171b816dc9a · Zeichen 3163–3687 im Abschnitt
Wechselwirkungen · Tandemact
Tandemact 30 mg/2 mg tablets Tandemact 30 mg/4 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-115613 · Präparat HOS-094329
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4.
In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel
blockers, and HMGCoA reductase inhibitors are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) phenprocoumon (HOS-091031) calcium (HOS-085615) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-09-13T13:32:00Z · SHA-256 2f687843aaa08f3b2b5add2ddc427b0f290d7d4b353b767838c175de06dc93d0 · Passage 85cf85e270341e1f6e4c76ef9e007a4e2939afc6caf970ffcd8a8245b8364d15 · Zeichen 992–1639 im Abschnitt
Wechselwirkungen · Nexavar
Nexavar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-115752 · Präparat HOS-094353
Sorafenib inhibited CYP2B6, CYP2C8 and CYP2C9 in vitro with similar potency. However, in
clinical pharmacokinetic studies, concomitant administration of sorafenib 400 mg twice daily with
cyclophosphamide, a CYP2B6 substrate, or paclitaxel, a CYP2C8 substrate, did not result in a
clinically meaningful inhibition. These data suggest that sorafenib at the recommended dose of
400 mg twice daily may not be an in vivo inhibitor of CYP2B6 or CYP2C8.
Additionally, concomitant treatment with sorafenib and warfarin, a CYP2C9 substrate, did not result
in changes in mean PT-INR compared to placebo. Thus, also the risk for a clinically relevant in vivo
inhibition of CYP2C9 by sorafenib may be expected to be low. However, patients taking warfarin or
phenprocoumon should have their INR checked regularly (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): placebo (HOS-088378) phenprocoumon (HOS-091031) cyclophosphamide (HOS-084539) paclitaxel (HOS-087959) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-03-28T11:40:00Z · SHA-256 4561f7f7d54908430c2d44ab3a6a7808fbf136793e601e405c6fd3f8791d1b27 · Passage cb55cf6d7108a50263c9700216370a347c4099b73cd6ab7720e0916e5f13c35d · Zeichen 839–1657 im Abschnitt
Wechselwirkungen · RoActemra
RoActemra 20 mg/mL concentrate for solution for infusion · Abschnitt 4.5 · PDF-Seite 12
HOS-120235 · Präparat HOS-095117
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are
individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. methylprednisolone,
dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin,
calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or
benzodiazepines) must be monitored as doses may need to be increased to maintain therapeutic effect.
Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may
persist for several weeks after stopping therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) methylprednisolone (HOS-088374) theophylline (HOS-085910) phenprocoumon (HOS-091031) calcium (HOS-085615) dexamethasone (HOS-084535) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage 5813b1ce7c89db40984eac0f484f563bb69e2bde00d02c31bf6f777b49aba5a3 · Zeichen 1045–1677 im Abschnitt
Wechselwirkungen · RoActemra
RoActemra 162 mg solution for injection in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 45
HOS-120315 · Präparat HOS-095117
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are
individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. methylprednisolone,
dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin,
calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or
benzodiazepines) must be monitored as doses may need to be increased to maintain therapeutic effect.
Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may
persist for several weeks after stopping therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) methylprednisolone (HOS-088374) theophylline (HOS-085910) phenprocoumon (HOS-091031) calcium (HOS-085615) dexamethasone (HOS-084535) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage 5813b1ce7c89db40984eac0f484f563bb69e2bde00d02c31bf6f777b49aba5a3 · Zeichen 1102–1734 im Abschnitt
Wechselwirkungen · RoActemra
RoActemra 162 mg solution for injection in pre-filled pen · Abschnitt 4.5 · PDF-Seite 80
HOS-120388 · Präparat HOS-095117
When starting or stopping therapy with tocilizumab, patients taking medicinal products which are
individually adjusted and are metabolised via CYP450 3A4, 1A2 or 2C9 (e.g. methylprednisolone,
dexamethasone, (with the possibility for oral glucocorticoid withdrawal syndrome), atorvastatin,
calcium channel blockers, theophylline, warfarin, phenprocoumon, phenytoin, ciclosporin, or
benzodiazepines) must be monitored as doses may need to be increased to maintain therapeutic effect.
Given its long elimination half-life (t1/2), the effect of tocilizumab on CYP450 enzyme activity may
persist for several weeks after stopping therapy.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atorvastatin (HOS-086304) methylprednisolone (HOS-088374) theophylline (HOS-085910) phenprocoumon (HOS-091031) calcium (HOS-085615) dexamethasone (HOS-084535) phenytoin (HOS-084531) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-01T16:00:00Z · SHA-256 258d193083a3b6e0f9782afb87035df8942fd3b113f118da023f638cb2c019c8 · Passage 5813b1ce7c89db40984eac0f484f563bb69e2bde00d02c31bf6f777b49aba5a3 · Zeichen 1102–1734 im Abschnitt
Wechselwirkungen · Pantozol Control
PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-121270 · Präparat HOS-095311
Coumarin anticoagulants (phenprocoumon or warfarin)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-25T09:40:00Z · SHA-256 74b810d41ae676f9b6d4a8f91ac3b9f2a6bb2766634c7fe3fe9823d5e550ca6b · Passage b6bef5b1c9d4886cd134b41d5e5ff1bb9dc3f7be46272674fcc25fecc1ef2c57 · Zeichen 479–530 im Abschnitt
Wechselwirkungen · Pantozol Control
PANTOZOL Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-121271 · Präparat HOS-095311
Although no interaction during concomitant administration of phenprocoumon or warfarin has been
observed in clinical pharmacokinetic studies, a few isolated cases of changes in International
Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing
period. Therefore, in patients treated with coumarin anticoagulants (e.g., phenprocoumon or warfarin),
monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular
use of pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-25T09:40:00Z · SHA-256 74b810d41ae676f9b6d4a8f91ac3b9f2a6bb2766634c7fe3fe9823d5e550ca6b · Passage 7a6a7807c668d0252e96a04dbeb0b6455b753840823a47206df713e6135e14f7 · Zeichen 532–1039 im Abschnitt
Wechselwirkungen · Controloc Control
CONTROLOC Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-121763 · Präparat HOS-095429
Coumarin anticoagulants (phenprocoumon or warfarin)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-25T09:08:00Z · SHA-256 e7bfcc80e0d744a3ae6dc7e45d026433d68d865a95e0e5185c1771cd63eb461e · Passage b6bef5b1c9d4886cd134b41d5e5ff1bb9dc3f7be46272674fcc25fecc1ef2c57 · Zeichen 480–531 im Abschnitt
Wechselwirkungen · Controloc Control
CONTROLOC Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-121766 · Präparat HOS-095429
Although no interaction during concomitant administration of phenprocoumon or warfarin has been
observed in clinical pharmacokinetic studies, a few isolated cases of changes in International
Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing
period. Therefore, in patients treated with coumarin anticoagulants (e.g., phenprocoumon or warfarin),
monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular
use of pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-25T09:08:00Z · SHA-256 e7bfcc80e0d744a3ae6dc7e45d026433d68d865a95e0e5185c1771cd63eb461e · Passage 7a6a7807c668d0252e96a04dbeb0b6455b753840823a47206df713e6135e14f7 · Zeichen 533–1040 im Abschnitt
Wechselwirkungen · Somac Control
SOMAC Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-211875 · Präparat HOS-154776
Coumarin anticoagulants (phenprocoumon or warfarin)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-24T09:32:00Z · SHA-256 6d8f7d6ff1a05f6ec91f06d93ac70bd03edb677073b9513b2006a963eea1d696 · Passage b6bef5b1c9d4886cd134b41d5e5ff1bb9dc3f7be46272674fcc25fecc1ef2c57 · Zeichen 476–527 im Abschnitt
Wechselwirkungen · Somac Control
SOMAC Control 20 mg gastro-resistant tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-211877 · Präparat HOS-154776
Although no interaction during concomitant administration of phenprocoumon or warfarin has been
observed in clinical pharmacokinetic studies, a few isolated cases of changes in International
Normalised Ratio (INR) have been reported during concomitant treatment in the post-marketing
period. Therefore, in patients treated with coumarin anticoagulants (e.g., phenprocoumon or warfarin),
monitoring of prothrombin time/INR is recommended after initiation, termination or during irregular
use of pantoprazole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): coumarin (HOS-088372) phenprocoumon (HOS-091031) prothrombin (HOS-085093) warfarin (HOS-085950)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-05-24T09:32:00Z · SHA-256 6d8f7d6ff1a05f6ec91f06d93ac70bd03edb677073b9513b2006a963eea1d696 · Passage 7a6a7807c668d0252e96a04dbeb0b6455b753840823a47206df713e6135e14f7 · Zeichen 529–1036 im Abschnitt
Wechselwirkungen · Incresync
Incresync 12.5 mg/30 mg film-coated tablets Incresync 25 mg/30 mg film-coated tablets Incresync 25 mg/45 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-124685 · Präparat HOS-095913
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4.
In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel
blockers and HMGCoA reductase inhibitors, are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) phenprocoumon (HOS-091031) calcium (HOS-085615) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-09-09T12:31:00Z · SHA-256 cbd1851f0d7bf897be948ef8b74484626964929eb5e4c45499b1be3f0ce7ae66 · Passage 5732254378306b19997b260af08f91b3f268e2c4a18e75dd538352d92da57c0e · Zeichen 1289–1935 im Abschnitt
Wechselwirkungen · Pioglitazone Accord
Pioglitazone Accord 15 mg tablets Pioglitazone Accord 30 mg tablets Pioglitazone Accord 45 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-214041 · Präparat HOS-155248
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. In
vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) phenprocoumon (HOS-091031) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-08-27T02:00:00Z · SHA-256 3d9c32c106b92ea111d2cd14918d84ab542567902b7440d4cfc8889aa3bb0c68 · Passage 5992d5da88d12c669a6e3c010d5e96ad89323c23c881db938098c1f75466ac26 · Zeichen 0–485 im Abschnitt
Wechselwirkungen · Pioglitazone Actavis
Pioglitazone Actavis 15 mg tablets Pioglitazone Actavis 30 mg tablets Pioglitazone Actavis 45 mg tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-214487 · Präparat HOS-155342
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics
or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of
pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4.
In vitro studies have shown no inhibition of any subtype of cytochrome P450. Interactions with
substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel
blockers, and HMGCoA reductase inhibitors are not to be expected.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): digoxin (HOS-086172) phenprocoumon (HOS-091031) calcium (HOS-085615) warfarin (HOS-085950) metformin (HOS-091032)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-06-01T02:00:00Z · SHA-256 ad23e703c99e588d5e3753a426a2d517a2d2fd35bbce3778e82f258ef487d9a7 · Passage 85cf85e270341e1f6e4c76ef9e007a4e2939afc6caf970ffcd8a8245b8364d15 · Zeichen 0–647 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.